Table 1 Characteristics of included studies
First author, Years | Study design | Subject | Number | Experimental | Comparators | Study duration | Outcome measures |
|---|---|---|---|---|---|---|---|
Barbanoj [25], 2003 | RCT, crossover study | healthy | 18 | FEX 120 mg n = 18 | EBA 20 mg.. n = 18; PL n = 18 | 5 days | Wheal, flare, AE, sedative effects |
Boyle [36], 2005 | RCT, crossover study | healthy | 18 | FEX 60 mg, n = 18 | LOR 10 mg, n = 18; PL n = 18 | 2 months | Wheal, flare, AE, sedative effects |
Larbig [57], 2006 | RCT, crossover study | healthy | 30 | FEX 120 mg, n = 30 | PL n = 30 | 24 h | Wheal, flare |
Simons [55], 2002 | RCT, parallel study | healthy | 21 | FEX 180 mg, n = 7 | CHL 8 mg, n = 7; LOR 10 mg, n = 7 | 9 days | Wheal, flare |
Simons [31], 2003 | RCT, crossover study | healthy | 15 | FEX 30 mg, n = 15 | CET 10 mg, n = 15 | 24 h | Wheal, flare, sedative effects |
Takahashi [56], 2004 | RCT, crossover study | healthy | 7 | FEX 120 mg, n = 7 | BEP 20 mg, n = 7; PL n = 7 | 24 h | Wheal, flare, VAS of drowsiness |
Finn [11], 1999 | RCT, parallel study | CIU | 439 | FEX 40 mg/ 120 mg/240 mg/480 mg, n = 349 | PL n = 90 | 4 weeks | AE, sedative effects |
Berger [41], 2006 | RCT, parallel study | AR | 432 | FEX 180 mg, n = 288 | PL n = 144 | 15 days | AE, sedative effects |
Berkowitz [42], 2006 | RCT, crossover study | AR | 63 | FEX 180 mg, n = 63 | PL n = 63 | 2 weeks | AE, sedative effects |
Boyle [43], 2006 | RCT, crossover study | healthy | 18 | FEX 120 mg, n = 18 | CHL 6 mg, n = 18; PL n = 18 | 10 h | AE, sedative effects |
Bronsky [10], 1998 | RCT, parallel study | AR | 548 | FEX 80 mg/ 120 mg/ 240 mg, n = 411 | PL n = 137 | 14 days | AE, sedative effects |
Casale [13], 1999 | RCT, parallel study | AR | 861 | FEX 120 mg/ 180 mg, n = 569 | PL n = 292 | 3 weeks | AE, sedative effects |
Van Cauwenberge [17], 2000 | RCT, parallel study | AR | 685 | FEX 120 mg, n = 232 | LOR 10 mg, n = 228; PL n = 225 | 14 days | AE, sedative effects |
Day [33], 2004 | RCT, parallel study | AR | 575 | FEX 180 mg, n = 239 | CET 10 mg, n = 240; PL n = 96 | 24 h | AE, sedative effects |
Ramesh [50], 2013 | RCT, parallel study | AR | 50 | FEX 120 mg, n = 25 | CHL 4 mg, n = 25 | 14 days | AE, sedative effects |
Grant [14], 1999 | RCT, crossover study | healthy | 14 | FEX 60 mg, n = 14 | CET 10 mg, n = 14; EPI 20 mg, n = 14; TER 60 mg, n = 14; LOR 10 mg, n = 14; PL n = 14 | 24 h | AE, sedative effects |
Grant [23], 2002 | RCT, crossover study | healthy | 18 | FEX 180 mg, n = 18 | EBA 10 mg, n = 18; LOR 10 mg, n = 18; MIZ 10 mg, n = 18; PL n = 18 | 24 h | AE, sedative effects |
Hampel [26], 2003 | RCT, parallel study | AR | 495 | FEX 180 mg, n = 248 | CET 10 mg, n = 247 | 2 weeks | AE, sedative effects |
Hampel [45], 2007 | RCT, parallel study | AR | 393 | FEX 30 mg/ 60 mg, n = 193 | PL n = 200 | 8 days | AE, sedative effects |
Hashiguchi [52], 2016 | RCT, crossover study | healthy | 126 | FEX 120 mg, n = 126 | BIL 10 mg/ 20 mg, n = 252; PL n = 126 | 3 days | AE, sedative effects |
Hindmarch [24], 2002 | RCT, crossover study | healthy | 15 | FEX 360 mg, n = 15 | PRO 30 mg n = 15, PL n = 15 | 7 h | AE, sedative effects, CFF, CRT, LARS |
Hindmarch [15], 1999 | RCT, crossover study | healthy | 24 | FEX 120 mg, n = 24 | PRO 30 mg, n = 24; LOR 10 mg, n = 24; PL n = 24 | 24 h | AE, sedative effects, CFF, CRT, LARS |
Horak [20], 2001 | RCT, crossover study | AR | 40 | FEX 120 mg, n = 40 | CET 10 mg, n = 40; PL n = 40 | 2 days | AE, sedative effects |
Horak [48], 2010 | RCT, crossover study | allergic volunteers | 75 | FEX 120 mg, n = 70 | CET 10 mg, n = 68; BIL 20 mg, n = 74; PL n = 70 | 2 days | AE, sedative effects |
Horak [34], 2005 | RCT, crossover study | allergic volunteers | 94 | FEX 120 mg, n = 94 | PL n = 94 | 2 days | AE, sedative effects |
Howarth [16], 1999 | RCT, parallel study | AR | 722 | FEX 120 mg/ 180 mg, n = 421 | CET 10 mg, n = 209; PL n = 209 | 2 weeks | AE, sedative effects |
Inami [53], 2016 | RCT, crossover study | healthy | 20 | FEX 60 mg, n = 20 | DIP 50 mg, n = 20; PL n = 20 | 6 h | AE, sedative effects, LARS |
Kaiser [47], 2008 | RCT, parallel study | AR | 835 | FEX 120 mg, n = 359 | LOR 10 mg, n = 357; PL n = 119 | 7 days | AE, sedative effects |
Kaiser [21], 2001 | RCT, parallel study | AR | 836 | FEX 120 mg, n = 360 | LOR 10 mg, n = 357; PL n = 119 | 7 days | AE, sedative effects |
Kamei [49], 2012 | RCT, crossover study | healthy | 24 | FEX 60 mg, n = 24 | PRO 25 mg, n = 24; OLO 5 mg, n = 24; PL n = 24 | 8 h | AE, sedative effects, CFF, CRT, LARS |
Kamei [28], 2003 | RCT, crossover study | healthy | 11 | FEX 120 mg, n = 11 | d-CHL 4 mg, n = 11; OLO 10 mg, n = 11; PL n = 11 | 8 h | AE, sedative effects, CFF, CRT, CTT, LARS |
Mansfield [29], 2003 | RCT, crossover study | healthy | 42 | FEX 180 mg, n = 42 | DIP 50 mg, n = 42; PL n = 42 | 2 h | AE, sedative effects |
Milgrom [46], 2007 | RCT, parallel study | AR | 453 | FEX 60 mg, n = 222 | PL n = 231 | 2 weeks | AE, sedative effects |
Okubo [44], 2006 | RCT, crossover study | healthy | 9 | FEX 60 mg, n = 9 | EPI 20 mg, n = 9; PL n = 9 | 5 h | AE, sedative effects |
Okubo [54], 2016 | RCT, parallel study | AR | 747 | FEX 120 mg, n = 247 | BIL 20 mg, n = 249; PL n = 251 | 2 weeks | AE, sedative effects |
Prenner [18], 2000 | RCT, crossover study | AR | 929 | FEX 120 mg, n = 457 | LOR 10 mg, n = 472 | 14 days | AE, sedative effects |
Purohit [22], 2001 | RCT, crossover study | healthy | 26 | FEX 120 mg/ 180 mg, n = 52 | CET 10 mg, n = 26; PL n = 26 | 24 h | AE, sedative effects |
Purohit [35], 2004 | RCT, crossover study | healthy | 42 | FEX 180 mg, n = 42 | CET 10 mg, n = 42 | 4 h | AE, sedative effects |
Ridout [30], 2003 | RCT, crossover study | healthy | 18 | FEX 180 mg, n = 18 | HYD 50 mg, n = 18; PL n = 18 | 5 h | AE, sedative effects, CFF, CRT, LARS |
Schapowal [39], 2005 | RCT, parallel study | AR | 220 | FEX 180 mg, n = 113 | PL n = 107 | 14 days | AE, sedative effects |
Schoepke [51], 2013 | RCT, crossover study | healthy | 18 | FEX 120 mg, n = 18 | PL n = 18 | 24 h | AE, sedative effects |
Simons [9], 1997 | RCT, crossover study | healthy | 20 | FEX 120 mg, n = 40 | LOR 10 mg, n = 20 PL n = 20 | 24 h | AE, sedative effects |
Tsuda [40], 2005 | RCT, crossover study | healthy | 10 | FEX 120 mg, n = 10 | CET 5 mg/10 mg, n = 20; LOR 10 mg, n = 10; PL n = 10 | 24 h | AE, sedative effects |
Wahn [32], 2003 | RCT, parallel study | AR | 935 | FEX 30 mg, n = 464 | PL n = 471 | 14 days | AE, sedative effects |
Weiler [19], 2000 | RCT, crossover study | healthy | 40 | FEX 60 mg, n = 40 | DIP 50 mg, n = 40; PL n = 40 | 5 h | AE, sedative effects, VAS of drowsiness |
Ballmer-Weber [12], 1999 | RCT, crossover study | healthy | 20 | FEX 180 mg, n = 20 | CET 10 mg, n = 40; ACR 8 mg, n = 20 | 1 h | sedative effects |
Day [37], 2005 | RCT, parallel study | AR | 599 | FEX 180 mg, n = 250 | CET 10 mg, n = 249; PL n = 100 | 7 h | sedative effects |
Handa [27], 2004 | RCT, parallel study | CIU | 97 | FEX 180 mg, n = 45 | CET 10 mg, n = 52 | 28 days | sedative effects |
Hyo [38], 2005 | RCT, parallel study | healthy | 113 | FEX 120 mg, n = 28 | CET 10 mg, n = 30; LOR 10 mg, n = 28; PL n = 27 | 2 days | sedative effects |
Ridout [58], 2002 | RCT, crossover study | healthy | 24 | FEX 120 mg, n = 24 | PRO 25 mg, n = 24; PL n = 24 | 8 h | CFF, CRT, CTT, LARS |
Naicker [59], 2013 | RCT, crossover study | healthy | 11 | FEX 180 mg, n = 11 | PRO 25 mg, n = 11; LOR 10 mg, n = 11; PL n = 11 | 3 h | CRT, CTT, VAS of drowsiness |